## What we claim is:


(A

- A composition comprising a cationic liposome containing a cationic lipid, phosphatidylcholine and cholestrol.
- 2. A composition of claim 1 wherein the liposome contains an antisense oligonucleotide sequence.
- 3. A composition of claim 2 wherein the antisense sequence is a <u>raf</u> oligodeoxynucleotide.

A composition of claim 3 wherein the antisense sequence is of the formula 5'-GTGCTCCCATTGATGC-3' wherein only the terminal sequences are phosphorothicated.

- 5. A composition of claim 1 in a pharmaceutically acceptable carrier.
- 6. A composition of claim 4 in a pharmaceutically acceptable carrier.
- 7. A composition of claim 1 wherein the pharmaceutically acceptable carrier is isotonic.
- 8. A composition of claim 4 wherein the pharmaceutically

ιħ



- A method of radiosensitizing tumor tissue by administration of a radiosensitizing effective amount of at least one antisense oligonucleotide of no more than 40 bases containing the sequence 5'-GTGCTCCATTGATGC-3'.
  - 10. A method of claim 9 wherein the oligonucleotide is phosphorothicated at only the end nucleotides.
  - 11. A method of claim 9 wherein the oligonucleotide is phosphrothicated at only the end nucleotides.
  - 12. A method of claim 9 wherein the oligonucleotide is administered intravenously.
  - 13. A method of claim 9 wherein the oligonucleotide is administered directly to the target tissue.
  - 14. A method of claim 9 wherein the oligonucleotide is administered into the arterial supply to the target tissue.
  - 15. A method of claim 9 wherein the oligonucleotide is of the formula 5'-GTGCTCCATTGATCC-3' and only the end bases only are phosphorothioted.

Sub Jo.

A composition of matter comprising liposomes containing the sequence 5'-GTGCTCCATTGATGC-3' in a pharmaceutically acceptable carrier.

17. A composition of claim 1 wherein the cationic lipid is dimethyldioctadecyl ammonium bromide.

ALA